Protein drugs post-translational modification

Target Information database - The Database contains information such as Protein-Protein interactions, Metabolic and Signaling Pathways, Transcription factors, post-Translational modifications, Disease information, various Drugs and Clinical compounds and the Companies of interest. 

Given these definitions, FOPs would likely be considered pharmaceutical alternatives if one presumes that pioneer and follow-on proteins are identical at a precursor stage, prior to potential post-translational modification. This presumption may also be consistent with the similarity standard the agency applies to ascertain orphan drug status (see discussion in Section 1.2.6). Follow-on proteins cannot be considered to be therapeutic equivalents since they are not pharmaceutical equivalents and cannot be expected to have the same clinical effect and safety profile in the absence of testing. This assertion is supported by the following ... 

---